Updated:
Insitro
Daphne Koller founded Insitro in 2018 to apply machine learning to drug discovery, integrating cellular data with clinical data.
Insitro
Daphne Koller, a Stanford professor and co-founder of Coursera, started Insitro in 2018 to bridge the gap between machine learning and drug development. The company was built on the thesis that large, multi-modal datasets—from lab-generated cellular data to clinical records—could enable better predictions in therapeutic R&D. Insitro’s strategy combines wet-lab biology with computational modeling. It targets metabolism, oncology, and neuroscience through both wholly-owned programs and partnered collaborations. The firm generates its own high-throughput cellular data, applies ML to find causal disease insights, and designs small molecules or biologics around those targets. Koller has described the approach as “building a different kind of drug company” that uses prediction to improve the low success rate of traditional pharma R&D. The company is headquartered in South San Francisco and employs a cross-disciplinary team spanning biologists, data scientists, and engineers. It does not disclose AUM, deployment figures, or any outside investment structure; its public posture is that of a private operating company. No recent operational event from the last 24 months was confirmed through public sources. Insitro’s structural differentiator is its founder-led, company-integrated model: rather than acting as a venture firm that funds external startups, it operates a single R&D organization where ML scientists and biologists work side by side under one roof. This architecture is designed to avoid the translation gaps that often separate academic AI labs from pharma partners.
General information
Firm type
other
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Daphne Koller
CEO & Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Insitro?
Insitro is not structured as an investment firm. It is a drug-discovery company founded and run by Daphne Koller, who serves as CEO. There is no CIO or investment committee; capital allocation decisions are made by Koller and her executive leadership team as part of R&D planning.
Is Insitro a family office, venture firm, or operating company?
Insitro presents itself as an operating drug company, not a family office or venture firm. It does not manage outside capital, run an investment fund, or disclose AUM. Its public-facing activity is entirely focused on building a pipeline of therapeutic programs.
What investment stages does Insitro target?
Insitro does not invest in external companies. It designs its own drug programs from discovery through early clinical development, using internal resources and partnered collaborations. It does not participate in venture rounds, fund commitments, or co-investments.
How does Insitro source proprietary deal flow?
Insitro generates its own therapeutic hypotheses through its internal ML platform, which combines high-throughput cellular data with clinical data. It does not rely on external sourcing for deal flow. It has also entered partnered collaborations with pharma companies to co-develop programs emerging from this platform.
What is the origin of Insitro's wealth or funding?
Insitro is a private company and does not disclose its ownership structure. Its original funding rounds included venture capital investors such as Andreessen Horowitz and GV. The company may have additional institutional or individual backers, but no family office or single-wealth origin has been publicly identified.
How is Insitro related to other Koller ventures?
Daphne Koller is also a co-founder of Coursera and a former Stanford professor. Insitro is a separate entity with its own management and operations. There is no disclosed investment or governance link between Insitro and Coursera or any other Koller-related entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: